← Back to Search

Anticoagulant

Apixaban for Stroke (ARCADIA Trial)

Q: Has Apixaban been accepted by the FDA?

<p>There is both animal and human data supporting <a href="https://www.withpower.com/clinical-trials/apixaban">Apixaban</a>'s safety, so it received a score of 3.</p>

Phase 3

Waitlist Available

Led By Mitchell SV Elkind, MD

Research Sponsored by Columbia University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 7 years

Awards & highlights

ARCADIA Trial Summary

This trial is testing whether apixaban is better than aspirin at preventing another stroke in patients who have had a cryptogenic ischemic stroke and have atrial cardiopathy.

Eligible Conditions

Stroke

ARCADIA Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 7 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~7 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 7 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Incidence of recurrent stroke

Secondary outcome measures

Incidence of death from any cause

Incidence of major hemorrhage other than intracranial hemorrhage

Incidence of recurrent ischemic stroke or systemic embolism

+2 more

Side effects data

From 2018 Phase 4 trial • 557 Patients • NCT01884337

Incision site pain

100%

80%

60%

40%

20%

Study treatment Arm

TOTAL KNEE REPLACEMENT (TKR)

TOTAL HIP REPLACEMENT (THR)

ARCADIA Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Active agent: ApixabanExperimental Treatment1 Intervention

Patients with a recent embolic stroke of undetermined source (ESUS) and evidence of atrial cardiopathy will receive Apixaban

Group II: Active control: AspirinActive Control1 Intervention

Patients with a recent embolic stroke of undetermined source (ESUS) and evidence of atrial cardiopathy will receive Aspirin

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Apixaban

2011

Completed Phase 4

~132290

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of WashingtonOTHER

1,738 Previous Clinical Trials

1,843,336 Total Patients Enrolled

15 Trials studying Stroke

7,587 Patients Enrolled for Stroke

Weill Medical College of Cornell UniversityOTHER

1,054 Previous Clinical Trials

1,315,513 Total Patients Enrolled

13 Trials studying Stroke

5,094 Patients Enrolled for Stroke

Bristol-Myers SquibbIndustry Sponsor

2,638 Previous Clinical Trials

4,127,499 Total Patients Enrolled

9 Trials studying Stroke

22,082 Patients Enrolled for Stroke

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there other scientific papers that mention Apixaban?

"First studied in 2002 at Institut Curie Hopital, apixaban has completed 621 clinical trials. 222 trials are still recruiting, with a significant portion of these based in Toronto, Canada."

Answered by AI

What is Apixaban's main therapeutic purpose?

"Apixaban is commonly used to treat deep vein thrombosis, but it can also help prevent death by myocardial infarction, back, and percutaneous coronary intervention (pci)."

Answered by AI

Has Apixaban been accepted by the FDA?

"There is both animal and human data supporting Apixaban's safety, so it received a score of 3."

Answered by AI

Has a clinical trial like this been conducted before?

"As of now, there are 222 ongoing trials for the drug Apixaban in 65 countries and 1503 cities. The first study was completed in 2002 and it reached the third and final stage of drug approval. The study had 413 participants and was sponsored by the company Sanofi. In the 18 years since the initial study, 621 more trials have been completed."

Answered by AI